

Breast Cancer Index (BCI) Patient Eligibility Criteria

Thank you for choosing BCI to provide your patients the personalized information they need. We believe all eligible patients deserve to know the appropriate duration of therapy for them.

Please refer to the table below to ensure your patient is eligible for testing.

Criteria	Accepted
Sex	<ul style="list-style-type: none"> Biologically female
Hormone Receptor Status	<ul style="list-style-type: none"> ER+ / PR+ ER+ / PR- ER- / PR+
Breast Cancer Type	<ul style="list-style-type: none"> Breast primary invasive tumor Multifocal tumor (same specimen) Bilateral Breast Cancer (BBC) Contralateral new primary Local recurrence has occurred (submit original tumor or biopsy) Invasive ductal carcinoma including most unusual subtypes such as mucinous, tubular, medullary, micropapillary, papillary, cribriform
Biopsy Site	<ul style="list-style-type: none"> Breast
Nodal Status	<ul style="list-style-type: none"> Node-negative (pN0) Isolated tumor cell clusters (ITC) (pN0(i+)) Micrometastases in 1-3 lymph nodes (pN1mi) Node positive with 1-3 positive lymph nodes (pN1) No lymph node dissection (pNX) Unknown nodal status
Tumor Size	<ul style="list-style-type: none"> T1, T2, T3
Tumor Grade	<ul style="list-style-type: none"> 1, 2, 3
HER2 Status	<ul style="list-style-type: none"> HER2- HER2+
Menopausal Status	<ul style="list-style-type: none"> Pre-Menopausal Post-Menopausal Peri-Menopausal
Adjuvant Treatment	<ul style="list-style-type: none"> Tamoxifen Aromatase Inhibitor <p><i>(Submit specimen obtained prior to initiation of treatment)</i></p>

See reverse for ineligible criteria

Please see below about what types of patients
ARE NOT eligible for testing.

Criteria	Not Accepted
Sex	<ul style="list-style-type: none">• Biologically male
Hormone Receptor Status	<ul style="list-style-type: none">• ER- and PR-
Breast Cancer Type	<ul style="list-style-type: none">• Metastatic breast cancer• No evidence of invasive (ductal, lobular or mixed ductal lobular) carcinoma• Metaplastic breast cancer• Carcinosarcoma• Sarcoma• Neuroendocrine carcinoma• Phyllodes tumor• Adenoid cystic carcinoma
Biopsy Site	<ul style="list-style-type: none">• Chest wall• Lymph node• Skin
Nodal Status	<ul style="list-style-type: none">• ≥ 4 positive nodes
Tumor Size	<ul style="list-style-type: none">• Tis (DCIS)• Tis (LCIS)• T4• Microinvasive carcinoma T1mi

**Please contact us
if you have any questions**

Client Services:

Phone: (877) 886-6739

Fax: (800) 266-9607

Email: ClientServices@Biotheranostics.com

NOTE: This document is intended to educate physicians on eligibility criteria for Breast Cancer Index testing. For Medicare coverage criteria under the Local Coverage Determination and the full Intended Use and Limitations, please visit breastcancerindex.com.

© 2024 Hologic, Inc. All rights reserved.

Hologic, Breast Cancer Index, and associated logos are trademarks and/or registered trademarks of Hologic, Inc. and/or its subsidiaries in the United States and/or other countries.